Managing patients with asthma continues to grow more complex. Two key guidelines have recently been updated. Where do their recommendations concur? Where do they differ, and why? Where do the newer biologic agents fit into evolving treatment paradigms? Which patients are likely to benefit, and in which are specific biologics inappropriate?
These are some of the questions we discuss with Dr. Ashraf Fawzy, from the Division of Pulmonology and Critical Care at Johns Hopkins University, in this ePulmonology Review podcast.
Podden och tillhörande omslagsbild på den här sidan tillhör
ePulmonology Review. Innehållet i podden är skapat av ePulmonology Review och inte av,
eller tillsammans med, Poddtoppen.
